Tianjin Pharmaceutical Da Ren Tang Group issues April update on subsidiary’s bankruptcy

SGX Filings

Apr 30

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Apr, 30 2026 that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update issued on Mar, 30 2026.

The company stated it will continue to monitor the court-supervised process, keep open communication with the administrator, and release further monthly updates as required under Rule 704(23) of the Listing Manual.

Tianjin Pharmaceutical Da Ren Tang Group also advised shareholders and potential investors to exercise caution when trading its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1114062109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114062109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114062109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114062109","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Group issues April update on subsidiary’s bankruptcy","media":"SGX Filings","content":"\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Apr, 30 2026 that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update issued on Mar, 30 2026.</p>\n<p>The company stated it will continue to monitor the court-supervised process, keep open communication with the administrator, and release further monthly updates as required under Rule 704(23) of the Listing Manual.</p>\n<p>Tianjin Pharmaceutical Da Ren Tang Group also advised shareholders and potential investors to exercise caution when trading its shares.</p>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Group issues April update on subsidiary’s bankruptcy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Group issues April update on subsidiary’s bankruptcy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-04-30 18:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Apr, 30 2026 that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update issued on Mar, 30 2026.</p>\n<p>The company stated it will continue to monitor the court-supervised process, keep open communication with the administrator, and release further monthly updates as required under Rule 704(23) of the Listing Manual.</p>\n<p>Tianjin Pharmaceutical Da Ren Tang Group also advised shareholders and potential investors to exercise caution when trading its shares.</p>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"达仁堂","start_time":0,"source_url":"","article_id":"1114062109","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114062109","pubTimestamp":1777544385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Apr, 30 2026 that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂"},"translate_title":"天津医药大仁堂集团发布子公司破产4月动态","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":1},"content_text":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Apr, 30 2026 that there have been no material developments in the bankruptcy liquidation of its 55%-owned subsidiary, Tianjin Shin Poong Pharmaceutical Co., Ltd., since the previous update issued on Mar, 30 2026.\nThe company stated it will continue to monitor the court-supervised process, keep open communication with the administrator, and release further monthly updates as required under Rule 704(23) of the Listing Manual.\nTianjin Pharmaceutical Da Ren Tang Group also advised shareholders and potential investors to exercise caution when trading its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}